PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

In vitro studies on prostate cancer: characteristics of PC3, DU145 and LNCaP cell lines
Article published in Urologia Polska 2007/60/3.

authors

Anna Stachurska, Michał Wronka, Hanna Maria Kowalczyńska
Zakład Biofizyki Centrum Medycznego Kształcenia Podyplomowego w Warszawie

keywords

prostate, prostate cancer, DU145, PC3, LNCaP, cell adhesion, cell adhesion molecules, cancer metastasis

summary

Prostate cancer is the second most common malignancy in men worldwide. Early diagnosis of the disease makes the therapy possible however patients with metastasis have a much lower recovery chance. In vitro studies carried out worldwide in the last decade, have raised hopes of solving the problem of the molecular mechanism of metastases, but despite many experiments some aspects of the metastasis process still remain unclear. In this review we present recent information on the prostate cancer cell lines PC3, DU145 and LNCaP, derived from bone, brain, and lymph node metastases, respectively. The characterization of membrane receptors, including cell adhesion molecules is described. We also demonstrate the putative mechanisms of migration, apoptosis and hormonal growth regulation of the above mentioned cells.

references

  1. Konig J E, Senege T, Allhoff E P., Konig W: Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2003, 58, 121-129.
  2. Krieger J N, Ross S O, Riley D E: Chronic prostatitis: epidemiology and role of infection. Urology 2002, 60 (6A), 8-12.
  3. Untergasser G, Madersbacher S, Berger P: Benign prostatic hyperplasia: age related tissue-remodeling. Exp Geront 2005, 40, 121-128.
  4. Schwartz K, Deschere B, Xu J: Screening for prostate cancer: Who and how oftenα J Fam Pract 2005, 54, 586-596.
  5. Jemal A, Tiwari R C, Murray T et al: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54, 8-29.
  6. Madeja Z, Miękus J, Sroka J et al: Homotypic cell-cell contacts stimulate the motile activity of rat prostate cancer cells. BJU Int 2001, 88, 776-786.
  7. Miękus K, Czernik M, Sroka J et al: Contact stimulation of prostate cancer cell migration: the role of gap junctional coupling and migration stimulated by heterotypic cell-to � cell contacts in determination of the metastatic phenotype of Dunning rat prostate cancer cells. Biol Cell 2005, 97, 893-903.
  8. Saiki J: Cell adhesion molecules and cancer metastasis. Jpn J Pharmacol 1997, 75, 215-242.
  9. Wang X, Ferreira A M, Shao Q et al: &betha;3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 2005, 63, 65-80.
  10. Folkman J: What is the evidence that tumors are angiogenesis dependentα J Natl Cancer Inst 1990, 82, 4-6.
  11. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1889, 1, 571-573. zob. Weiss L: Patterns of metastasis. Cancer Metastasis Rev 2000, 19, 281-301.
  12. Pinski J, Dorff TB: Prostate cancer metastases to bone: pathophysiology, pain management and the promise of targeted therapy. Eur J Cancer 2005, 41, 932-940.
  13. Sobel R E, Sadar M D: Cell lines used in prostate cancer research: a compendium of old and new lines � Part 1. J Urol 2005, 173, 342-359.
  14. Kaighn M E, Narayan S, Ohnuki Y et al: Establishment and characterization of a human prostatic carcinoma cell line (PC3). Investig Urol 1979, 17, 16-23.
  15. Webber MM, Bello D, Quader S: Immortalized epithelial cell lines: characteristics and Applications Part 2. Tumorgenic Cell Lines. Prostate 1997, 30, 58-64.
  16. Stone KR, Mickey DD, Wunderli H et al: Isolation of a human prostate carcionoma cell line (DU145). Int J Cancer 1978, 21, 274-281.
  17. Horoszewicz JS, Leong SS, Chu TM et al: The LNCaP cell line a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980, 37, 115-132.
  18. Meyer T, Hart IR: Mechanism of tumour metastasis. Eur J Cancer 1998, 34, 214-221.
  19. Yamaguchi H, Wyckoff J, Condeelis J: Cell migration in tumors. Curr Opin Cell Biol 2005, 17, 559-564.
  20. Albelda S: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993, 68, 4-17.
  21. Hynes RO: Integrins: versatility, modulation and cell adhesion. Cell 1992, 69, 11-25.
  22. Fornaro M, Manes T, Languino LR: Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001, 20, 321-331.
  23. Stewart DA, Cooper CR, Sikes RA: Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Rep Biol Endocrinol 2004, 2, 2-15.
  24. Schwartz MA, Ginsberg MH: Networks and crosstalk: integrin signaling spreads. Nat Cell Biol 2002, 4, 1465-1476.
  25. Alberts B, Bray D, Lewis J et al: Cells junctions, cell adhesion, and the extracellular matrix. Molecular biology of the cell. New York, London: Garland 1994, 995-999.
  26. Felding-Habermann B: Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003, 20, 203-213.
  27. Okegawa T, Li Y, Pong RC, Hsieh JT: Cell adhesion proteins as tumor suppressors. J Urol 2002, 167, 1836-1843.
  28. Tran NL, Nagle RB, Cress AE, Heimark RL: N-Cadherin expression in human prostate carcinoma cell lines. Am J Pathol 1999, 155, 787-798.
  29. Takeichi M: Cadherin Cell Adhesion Receptors as a Morphogenetic Regulator. Science 1991, 251, 1451-1455.
  30. Bussemakers MJG, van Bokhoven A, Tomita K et al: Complex cadherin expression in human prostate cancer cells. Int J Cancer 2000, 85, 446-450.
  31. Horvath L G, Henschall S M, Lee C-S et al: Lower levels of nuclear &betha;-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 2005, 113, 415-422.
  32. Tomita K, van Bokhoven A, Jansen CFJ et al: Coordinate recruitment of E-cadherin and ALCAM to cell�cell contacts by a-catenin. Biochem Biophys Res Commu 2000, 267, 870-874.
  33. Rokhlin O W, Cohen MB: Expression of cellular adhesion molecules on human prostate tumor Cell lines. Prostate 1995, 26, 205-212.
  34. Dimitroff CJ, Lechpammer M, Long-Woodward DL, Kutok JL: Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. Cancer Res 2004, 64, 5261-6269.
  35. Dimitroff CJ, Deschenny L, Trujilo N et al: Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res 2005, 65, 5750-5760.
  36. Orr F W, Wang HH, Lafrenie RM et al: Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000, 190, 310-329.
  37. Dorobek W: Zagadnienia endokrynologiczne, w: Borkowski A, Borówka A (red): Choroby gruczołu krokowego, Warszawa PZWL, 1997, 35-40.
  38. Edwards J, Bartlett JMS: The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005, 95, 1320-1326.
  39. Javidan J, Deitich AD, Shi X-B, de Vere White RW: The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invetst 2005, 23, 520-528.
  40. Hobisch A, Hittmair A, Daxenbichler G et al: Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 1997, 182, 356-361.
  41. Horvath LG, Henschall SM, Lee C-S et al: Frequent loss of estrogen receptor- &betha; in prostate cancer. Cancer Res 2001, 61, 5331-5335.
  42. Lau K-M, Laspina M, Long J, Ho S-M: Expression of estrogen receptor (ER) -α and ER-&betha; in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000, 60, 3175-3182.
  43. Connoly JM, Rose DP: Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor- related polypeptides. Prostate 1991, 19, 173-180.
  44. Barrack ER: TGF-&betha; in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997, 30, 61-70.
  45. Cooper CR, Bhatia J, Muenchen HJ et al: The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. Clin Exp Metastasis 2002, 19, 25-33.
  46. Angelucci A, Festuccia C, Gravina GL et al: Osteopontin enhances the cell proliferation induced by the Epidermal Growth Factor in human prostate cancer cells. Prostate 2004, 59, 157-166.
  47. Kwabi-Addo B, Ozen M, Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004, 11, 709-724.
  48. Freeman KW, Gangula RD, Welm BE et al: Conditional activation of Fibroblast Growth Factor Receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 2003, 63, 6237-6243.
  49. Keller ET, Zhang J, Cooper CR et al: Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001, 20, 333-349.
  50. Romanov VI, Whyard T, Adler HL et al: Prostate cancer cell adhesion to bone marrow endothelium: The role of prostate-specific antigen. Cancer Res 2004, 64, 2083-2089.
  51. Tomita K, van Bokhoven A, van Leenders GJLH et al: Cadherin switching in human prostate cancer progression. Cancer Res 2000, 60, 3650-3654.
  52. Cooper CR, Chay CH, Gendernalik JD et al: Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003, 97, 739-747.
  53. Biggerstaff JP, Seth N, Amirkhosravi A et al: Soluble fibrin augments platelet/ tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 1999, 17, 723-730.
  54. Trikha M, Raso E, Cai Y et al: Role of αIIb&betha;3 integrin in prostate cancer metastasis. Prostate 1998, 35, 185-192
  55. Glinsky VV, Glinsky GV, Rittenhouse-Olson K et al: The role of Thomsen- -Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001, 61, 4851-4857.
  56. Jacob K, Webber M, Benayahu D, Kleinman HK: Osteonectin promotes prostate cancer cell migration and invasion. Cancer Res 1999, 59, 4453-4457.
  57. Yoneda T: Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998, 34, 240-245.
  58. Scott LJ, Clarke NW, George NJ et al: Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer 2001, 84, 1417-1423.
  59. De S, Chen J, Narizheva NV et al: Molecular pathway for cancer metastasis to bone. J Biol Chem 2003, 278, 39044-39050.
  60. Murphy-Ullrich JE: The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive stateα J Clin Invest 2001, 107, 785-790.
  61. Zheng DQ, Woodard AS, Tallini G, Languino LR: Substrate Specifity of αv&betha;3 Integrin � mediated cell migration and Phosphatidyloinositol 3-kinase/ AKT Pathway activation. J Biol Chem 2000, 275, 24565-24574.
  62. Albrecht M, Renneberg M, Wennemuth G et al: Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol 1999, 112, 51-61.
  63. Cooper CR, Pienta KJ: Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 2000, 3, 6-12.
  64. Cooper C R, McLean L, Walsh M et al: Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to Extracellular matrix components in vitro. Clin Cancer Res 2000, 6, 4839-4847.
  65. Samsel L, Zaidel G, Drumgoole HM et al: The ceramide analog, B13 induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004, 58, 382-393.
  66. Kawiak J: Czy biologia molekularna może być pomocna w pracy lekarza urologaα w: Borówka A. Wykłady z urologii. Warszawa, Polskie Towarzystwo Urologiczne 2001, 123-125.
  67. Gasparian AV, Yao YJ, Kowalczyk D et al: The role of IKK in constitutive activation of NF-α&betha; transcription factor in prostate carcinoma cells. J Cell Sci 2002, 115, 141-151.
  68. Gurumurthy S, Vasudevan KM, Rangnekar VM: Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001, 20, 225-243.
  69. Quinn DI, Henshall SM, Sutherland RL: Molecular markers of prostate cancer outcome. Eur J Cancer 2005, 41, 858-887.
  70. Hara I, Miyake H, Hare S et al: Differential involvement of the Fas receptor/ ligand system in p53-dependent apoptosis in human prostate cancer cells. Prostate 2000, 45, 341-349.

correspondence

Anna Stachurska
Zakład Biofizyki CMKP
ul. Marymoncka 99
01-813 Warszawa
tel. 0 606 114 109
biofmat@cmkp.edu.pl
anna.stachurska1@wp.pl